Journal: Journal of theoretical biology
Article Title: Dynamic modeling of signal transduction by mTOR complexes in cancer.
doi: 10.1016/j.jtbi.2019.109992
Figure Lengend Snippet: Fig. 3. Temporal concentration of rapamycin for regimens I–IV. Since the plasma protein binding of the rapamycin is set aside, the concentration of free Cytosolic rapamycin is equal to its total concentration. Each regimen is simulated while scanning the “amount ± 20%” area (linearly stepped) around the dose administered. (A) Regimen Ⅰ : 8.0 × 10 −20 ± 20% mole/Day; (B) Regimen Ⅱ : 5.6 × 10 −19 ± 20% mole/Day; (C) Regimen Ⅲ : 5.6 × 10 −19 ± 20% mole/Week; and (D) Regimen Ⅳ : 2.24 × 10 −18 ± 20% mole/ Week.
Article Snippet: Contents lists available at ScienceDirect Journal of Theoretical Biology journal homepage: www.elsevier.com/locate/jtb Dynamic modeling of signal transduction by mTOR complexes in cancer Mohammadreza Dorvash a , b , 1 , Mohammad Farahmandnia b , c , 1 , Pouria Mosaddeghi a , b , c , 1 , Mitra Farahmandnejad a , b , c , Hosein Saber a , c , Mohammadhossein Khorraminejad-Shirazi b , c , Amir Azadi a , d , Iman Tavassoly e , ∗ a Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran b Cell and Molecular Medicine Student Research Group, Faculty of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran c Student Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran d Department of Pharmaceutics, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran e Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, 1425 Madison Ave, New York, NY 10029, USA a r t i c l e i n f o Article history: Received 10 May 2019 Revised 5 August 2019 Accepted 2 September 2019 Available online 4 September 2019 Keywords: Cell Signaling Mathematical Model mTOR Rapamycin Systems Biology Systems pharmacology a b s t r a c t Signal integration has a crucial role in the cell fate decision and dysregulation of the cellular signaling pathways is a primary characteristic of cancer.
Techniques: Concentration Assay, Clinical Proteomics, Protein Binding